GlassScriptPhysician profile
Jedd Douglas Walker
NPI 1326751132
$2,807.56
in general payments reported to CMS, 2019-2025
21 companies · $2,584 in 2025
The $2,584 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $51.28 · 2024: $172 · 2025: $2,584.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,517 · Food and Beverage: $1,239 · Entertainment: $30.83 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,517.46 |
| Food and Beverage | $1,239.05 |
| Entertainment | $30.83 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,991.36 | 2024-2025 | Minimed 780g |
| Lilly USA, LLC | $94.59 | 2024-2025 | Zepbound, Mounjaro |
| Insulet Corporation | $88.72 | 2025 | Omnipod |
| Xeris Pharmaceuticals, INC. | $74.37 | 2025 | Recorlev, Gvoke Hypopen |
| Inspire Medical Systems, INC. | $60.37 | 2023-2025 | Inspire |
| Corcept Therapeutics | $57.75 | 2025 | Korlym |
| Neurocrine Biosciences, INC. | $51.07 | 2025 | |
| Madrigal Pharmaceuticals | $49.51 | 2025 | Rezdiffra |
| Kyowa Kirin, INC. | $49.24 | 2024-2025 | Crysvita |
| Boehringer Ingelheim Pharmaceuticals, INC. | $45.70 | 2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $35.97 | 2024-2025 | |
| Eton Pharmaceuticals, INC. | $33.60 | 2024-2025 | Alkindi, Khindivi, Increlex |
| Ascendis Pharma Endocrinology INC | $31.19 | 2025 | Skytrofa, Yorvipath |
| Optos, INC. | $30.83 | 2024 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| Rhythm Pharmaceuticals, INC. | $19.74 | 2025 | Imcivree |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Chiesi USA, INC. | $18.78 | 2025 | Mycapssa |
| Radius Health, INC. | $18.18 | 2023 | Tymlos |
| Curonix LLC | $16.61 | 2024 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Novartis Pharmaceuticals Corporation | $15.22 | 2025 | |
| Novo Nordisk INC | $14.83 | 2025 | Wegovy |
| Phathom Pharmaceuticals, INC. | $9.93 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jedd Walker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.